CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|May 1, 2016
- BioPharm International-05-01-2016
- Volume 29
- Issue 5
Ultracentrifuge Allows for Multi-Wavelength Analysis
Listen
0:00 / 0:00
Key Takeaways
- The Optima AUC ultracentrifuge determines molecular weight, size, shape, and polydispersity with advanced features for comprehensive analysis.
- A 15-inch touch-screen and remote data export capabilities enhance user interaction and data management.
The Optima AUC from Beckman Coulter Life Sciences is an ultracentrifuge that determines molecular weight, size shape, and polydispersity.
Advertisement
The Optima AUC from Beckman Coulter Life Sciences is an ultracentrifuge that determines molecular weight, size shape, and polydispersity. The Optima AUC has a 38.1-cm (15-inch diagonal) touch-screen with the ability to export data locally or remotely. The optics are contained outside the rotor chamber, reducing the impact of the g-force on the optics. The Optima AUC also allows molecules to float free and unbound so that researchers are able to characterize them in their native state. The ultracentrifuge can perform multi-wavelength analysis and allows for the development of new detection systems.
Articles in this issue
over 10 years ago
Using Single-Use Systems in Aseptic Fill-Finishover 10 years ago
Filling and Closing System Reduces Decontamination Cycleover 10 years ago
Outsourcing of Biomanufacturing in 2016over 10 years ago
Reporting Quality Metrics to FDAover 10 years ago
The Value of Saving Livesover 10 years ago
Realizing the Potential of CAR-T Cell Therapiesover 10 years ago
Advancing cell therapy safetyAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement